Company: HURA
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001193125-25-260933
Chunk: 0

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-10-31
Form: 424B3
Chunk 0
---
Filed pursuant to Rule 424(b)(3)

Registration No. 333-289532

PROSPECTUS SUPPLEMENT NO. 1

<div align='center'>TUHURA BIOSCIENCES, INC.

Up to 4,570,629 Shares of Common Stock

Up to 4,750,916 Shares of Common Stock Issuable Upon Exercise of

Warrants

________________________________________</div>

This prospectus supplement supplements the prospectus dated September 26, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-289532) originally filed with the Securities and Exchange Commission (the “SEC”) on August 12, 2025 and declared effective by the SEC on September 26, 2025.

This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form 8-K filed with the SEC on October 31, 2025 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement.

The Prospectus and this prospectus supplement relate to the proposed offer and resale or other disposition from time to time by the selling stockholders identified in the Prospectus of up to an aggregate of up to (i) 4,570,629 shares of common stock, par value $0.001 per share, and (ii) 4,750,916 shares of common stock issuable upon the exercise of warrants.

Our shares of Common Stock are currently listed on the Nasdaq Capital Market under the symbols “HURA”.The last reported sale price of the common stock on October 30, 2025 was $2.48 per share.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 5 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or dis